Last reviewed 26 August 2026
The question usually arrives wanting a yes or a no, and the honest answer is a framework — because Irish law does not regulate “peptides” as a category at all. It regulates medicines: what may be placed on the market, what needs a prescription, and how medicines may and may not be sold. Whether a given vial falls inside those rules is decided by what it is and how it is presented, not by what its label disclaims. This article sets out the framework, with the statutory text behind each statement, and then says plainly where research-use supply sits within it.
Every statement here is a statement about a rule, a document or a register; none is a statement about what any compound does.
The framework, in four instruments
The Irish Medicines Board Act 1995 establishes the HPRA as Ireland’s competent authority for human medicines and takes its definition of a medicinal product directly from Directive 2001/83/EC — the same European code that governs the UK-adjacent regimes an Irish buyer may already have read about.
The Medicinal Products (Control of Placing on the Market) Regulations 2007 carry the central prohibition: a person shall not place a medicinal product on the market unless
it holds a marketing authorisation or equivalent certificate. The same regulations reach business possession — a person may not, in the course of business, sell, supply or possess a medicinal product without reasonable cause to believe it was or would be lawfully placed on the market.
The Medicinal Products (Prescription and Control of Supply) Regulations 2003 set the prescription rules, and one limb matters more than any schedule for this field: prescription control attaches not only to listed substances but to any medicinal product which is intended for parenteral administration
— any injectable medicine, automatically. The same regulations prohibit mail-order supply of medicinal products outright: A person shall not supply by mail order any medicinal product
, with supply defined to reach sellers outside the State. The Pharmaceutical Society of Ireland completes the online picture: prescription medicines cannot be sold on the internet in Ireland at all, and even non-prescription medicines may only be sold online by sellers registered with the PSI.
The Misuse of Drugs Regulations 2017 are the fourth instrument — covered below, mostly for what is not in them.
What makes something a medicine
Article 1(2) of Directive 2001/83/EC defines a medicinal product on two limbs: a substance presented as having properties for treating or preventing disease in human beings
, or one that may be administered with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action
. Presentation, or function.
The HPRA’s published classification guide shows how both limbs are applied. On presentation, claim language decides — cures; heals; treats; restores; prevents…
— and the test is what any averagely well-informed consumer
would take from the product’s whole presentation, implication included; though the courts have also held that a product’s external form cannot be the sole or conclusive evidence
. On function, the guide is blunter still: any product containing a substance with a known pharmacological effect at that dose level … will usually be classified as a medicinal product by the HPRA irrespective of the presence or absence of claims or medical purpose in the product packaging or literature
, and a product containing a substance that is prescription-only is generally deemed to be a medicinal product requiring an authorisation
.
Read those two limbs together and the position is symmetrical, and worth stating honestly because half this market states only one side of it: a label neither makes a product a medicine nor unmakes one. Writing “research use only” on a vial of a prescription-medicine active changes nothing — that is the function limb, and it is why grey-market semaglutide is detained by the tonne whatever its labels say. Equally, a laboratory reagent with no medicinal presentation and no authorised-medicine counterpart is not conjured into a medicine by its chemical class alone: classification runs case by case on the totality — claims (including linked websites), labelling, product form, audience, and similar authorised products on the market. The HPRA operates a formal classification service and a Borderline Products Committee for exactly these cases.
What research supply is allowed to look like
Irish medicines law expressly contemplates research supply. Regulation 20(1)(a)(i) of the 2003 Regulations disapplies the prescription rules and the mail-order prohibition for the supply of a medicinal product to a University or other institution concerned with higher education or scientific research for the purposes of such education or research
— even a full medicinal product may be supplied for research through that route. And the Directive itself does not apply to medicinal products intended for research and development trials
, nor to substances never placed on the market for human use: the code regulates medicines offered to people, not laboratory chemistry.
Where does that leave a research-peptide vial? In the space those provisions describe, provided the seller keeps it there: no medicinal presentation, no human-use purpose, no prescription-medicine actives. One absence should be recorded honestly — the HPRA has published no guidance specifically addressed to “research use only” peptide vials, so the doctrine above is the general framework any classification would apply, not a peptide-specific ruling. What can be said with confidence is which side of each line this site keeps to, set out at the end.
What is — and is not — in the controlled-drugs schedules
Here Ireland genuinely differs from the UK, and the difference is widely misunderstood in both directions. We searched the full text of the Misuse of Drugs Regulations 2017 as made: somatropin (growth hormone), anabolic agents, melanotan and the GLP-1 class appear nowhere in the Irish controlled-drugs schedules — where UK law, by contrast, makes somatropin and anabolic agents Class C controlled drugs. (Amending instruments since 2017 have mostly addressed psychoactive substances; we have found none adding these, but check the current consolidated schedules before relying on the point.)
Do not read that as a permission slip. Ireland polices these substances through medicines law instead, and polices them hard: anabolic steroids alone accounted for 203,088 detained dosage units in 2024 and 94,647 in 2025 — as unauthorised medicines, under the HPRA’s remit with Revenue’s Customs Service, not as controlled drugs under a Garda’s. A different statute, doing the same work at the border. What was detained, by whom and under which powers is the subject of the companion article, Do peptides get seized at Irish customs?
What the enforcement record targets
The HPRA’s published enforcement follows the presentation limb almost perfectly. What its releases describe being detained are products presented as medicines or consumer treatments: branded and “generic” pens, tablets, products typically presented as weight loss aids
, GLP-1 drops and microneedle patches — 48,752 GLP-1 units in 2025, against 1,582 the year before, with sampled patches found not to contain the semaglutide their packaging claimed. Alongside the parcels, 4,762 websites and listings were shut down or amended in 2025. The pattern is the doctrine in action: enforcement lands where medicinal presentation, prescription-medicine actives and consumer marketing meet.
Where NovoVita stands
Against that framework, our position is short. We make no medicinal claims anywhere — no treating, no preventing, no restoring; our copy is identity, presentation and storage, and our compound library documents the published literature with verified citations rather than promising anything. We sell no prescription-medicine actives: semaglutide, tirzepatide and their class are not offered for sale on this site and never have been — the reasoning is published. And our orders reach Ireland without meeting a customs border at all, moving as intra-EU trade under the Windsor Framework — the customs analysis is in Buying research peptides in Ireland.
What this article does not settle
Classification is case by case and the instruments above are amended over time — the linked statutory texts and HPRA documents are the authority, not this summary. Nothing here is a statement about any compound’s effects. Everything NovoVita supplies is for laboratory research use only and is not for human or veterinary use; a library entry is documentation of the published record, not a product. This is analysis, not legal advice, and for a specific situation it cannot substitute for advice from an Irish solicitor.
Sources
- Irish Medicines Board Act 1995 (revised text, Law Reform Commission) — the HPRA’s remit and the medicinal-product definition.
- S.I. No. 540 of 2007, Medicinal Products (Control of Placing on the Market) Regulations 2007 — regulation 6, the authorisation requirement.
- S.I. No. 540 of 2003, Medicinal Products (Prescription and Control of Supply) Regulations 2003 — regulation 5(1) (prescription classes, including parenteral products), regulation 19 (mail-order prohibition), regulation 20(1)(a)(i) (the research-institution exemption).
- S.I. No. 173 of 2017, Misuse of Drugs Regulations 2017 — the controlled-drugs schedules discussed above.
- HPRA, Guide to Definition of a Human Medicine (ADV-G0003-8, 21 December 2022) — classification by presentation and function, the totality factors and the Borderline Products Committee.
- Directive 2001/83/EC — Articles 1(2), 2 and 3.
- Pharmaceutical Society of Ireland, Internet supply — overview — the online-sale rules.
- HPRA, 2025 detention figures and 2024 detention figures.
- HPRA, HPRA warns of health risks of semaglutide type products sold illegally online (26 November 2024) — the formats and presentation of detained GLP-1 products.